iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
Globe Newswire (Tue, 1-Sep 4:30 PM ET)
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 28-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Market Chameleon (Wed, 1-Jul 7:09 AM ET)
Globe Newswire (Wed, 1-Jul 7:00 AM ET)
iBio’s Spotlight at Guggenheim Healthcare Conference Highlights Strategic Push in Obesity Innovation
Market Chameleon (Thu, 23-Oct 6:34 AM ET)
Market Chameleon (Tue, 21-Oct 6:28 AM ET)
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Ibio trades on the NASDAQ stock market under the symbol IBIO.
As of September 25, 2026, IBIO stock price declined to $1.19 with 614,830 million shares trading.
IBIO has a beta of 2.69, meaning it tends to be more sensitive to market movements. IBIO has a correlation of 0.10 to the broad based SPY ETF.
IBIO has a market cap of $76.53 million. This is considered a Micro Cap stock.
Last quarter Ibio reported $0 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-66,670 and met earnings estimates .
In the last 3 years, IBIO traded as high as $7.83 and as low as $.56.
The top ETF exchange traded funds that IBIO belongs to (by Net Assets): VTI, VXF, IWC.
IBIO has outperformed the market in the last year with a return of +49.4%, while the SPY ETF gained +18.4%. However, in the most recent history, IBIO shares have underperformed the stock market with its stock returning -25.2% in the last 3 month period and -1.2% for the last 2 week period, while SPY has returned +5.3% and +1.2%, respectively.
IBIO support price is $1.16 and resistance is $1.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBIO shares will trade within this expected range on the day.
